Abstract 273P
Background
We compared the diagnostic performance of cognitive transrectal MRI-targeted biopsy (MRITB) between three anatomical zones of the prostate.
Methods
Of the 569 initial cases with suspected prostate cancer, those who received standard biopsy (14-region, 18-core biopsy: SB) between June 2019 and March 2023 were selected (SB 57 cases, SB+MRITB 509 cases). SB alone was performed in PI-RADS v2.1 ≦2, and MRITB was added in ≧3. In this study, we investigated whether zonal anatomy affects the diagnostic performance of MRITB retrospectively.
Results
In 569 cases, 394 cases (69.2%) were positive for cancer. Of 394 cancer cases, 25 (6.3%) were from SB alone and 369 (93.7%) from SB+MRITB. According to the Epstein criteria, 359 cases (91.1%) were clinically significant. In all cases, the diagnostic performance of MRITB was 80.1% for sensitivity, 20.5% for specificity, 71.4% for positive predictive value, 29.4% for negative predictive value, and 63.0% for accuracy. The true positive rates of cancer detection by MRITB in each zone were 22 cores (43.1%) in CZ, 125 cores (41.9%) in TZ, and 283 cores (64.6%) in PZ. CZ and TZ groups were significantly lower than the PZ group, respectively, and especially, midgland TZ was the highest false-positive rates compared to midgland-apex TZ (87.3% v.s.33.3%).
Conclusions
In the case of SB including apex anterior biopsy, MRITB alone missed clinically significant cancers in 65 cases (18.1%) in PI-RADS v2.1 ≥3, which was a higher rate than those reported by many previous reports. In contrast, MRITB showed a high false-positive rate especially in TZ, suggesting that the positive criteria and approach model for these lesions need to be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Toyama.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract